Serum Institute To Supply Around 22 Crore Vaccine Doses

Serum Institute to supply around 22 crore doses of Covishield vaccine in October.

Amid the announcement by the central government to resume exports of additional vaccines in the fourth quarter under the ‘Tika Maitri’ program.

The Serum Institute of India (SII) has told the government that it will make available around 22 crore doses of Covishield in October

 Official sources have given this information.

Prakash Kumar Singh, director of government and regulatory affairs at SII, sent a letter to the Center on Monday.

saying that the company has increased its production capacity of covishield and it will be available to the government of India and private hospitals in October.

Will be able to supply 21.90 crore doses of vaccine.

The company also said that from January to the evening of September 19, it has provided 66.33 crore doses of Kovishield to the Union Health Ministry.

Apart from this, more than 7.77 crore doses have also been made available to state governments and private hospitals.

Singh has also said in the letter that keeping in mind the deadline, the company will fulfill the latest recent supply order of 66 crore doses by December 31.

The government will not buy vaccines from Pfizer-Moderna

According to the news agency Reuters, the government will not buy the anti-corona vaccines from American pharmaceutical companies Pfizer and Moderna.

Sources said that there has been sufficient availability of vaccines at the domestic level.

Indigenous vaccines are not only cheap as compared to foreign vaccines, but they are also easy to carry and apply anywhere.

The UK begins testing of booster vaccines against different variants

The UK has started a phase I trial of a booster vaccine against various variants of the coronavirus among people over the age of 60.

American pharmaceutical company Gritstone has linked GRT-R910 in collaboration with the University of Manchester and the University of Manchester NHS Foundation Trust Started this test.

It will explore the drug’s potential to boost immunity to first-generation corona vaccines.